CYCN
Cyclerion Therapeutics, Inc.Company Information
- Company Name
- Cyclerion Therapeutics, Inc.
- CIK
- CIK0001755237
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CYCN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CYCN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2024-11-21
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 357,880
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,276,390
- Shares outstanding
- 4,251,000
- Ownership
- 77.07%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 7.12%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 3 | 3 | 5 | 3 | 4 | 3 | 3 | 5 | 6 | 8 | 9 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | - | - | 0 | 0 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 2 | 3 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 10 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Long Term Investments | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Assets | 7 | 9 | 10 | 10 | 9 | 10 | 10 | 9 | 10 | 11 | 13 | 15 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Commitments And Contingencies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | 0 | 0 | 0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital Common Stock | 281 | 281 | 280 | 280 | 278 | 278 | 276 | 276 | 276 | 276 | 276 | 276 | ||||||
| Retained Earnings Accumulated Deficit | -276 | -274 | -271 | -270 | -269 | -269 | -267 | -268 | -267 | -266 | -264 | -263 | ||||||
| Stockholders Equity | 5 | 7 | 9 | 10 | 9 | 9 | 9 | 8 | 9 | 10 | 11 | 13 | ||||||
| Liabilities And Stockholders Equity | 7 | 9 | 10 | 10 | 9 | 10 | 10 | 9 | 10 | 11 | 13 | 15 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 1 | 1 | 1 | 100 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 20 | 20 | 20 | 400 | 20 | ||||||
| Common Stock Shares Issued | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Shares Outstanding | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCyclerion Therapeutics, Inc. (CYCN) — SEC Financial Statements & Analysis
Cyclerion Therapeutics, Inc. (CYCN) is a pharmaceutical preparations company, incorporated in MA. Cyclerion Therapeutics, Inc. trades on Nasdaq as: CYCN. Cyclerion Therapeutics, Inc. (CYCN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Cyclerion Therapeutics, Inc. carries a market cap of $100.88M, a P/E ratio of -15.04x, a P/B ratio of 19.83x, a P/S ratio of 53.09x, an enterprise value of $99.49M, and an EV/EBITDA multiple of -14.58x. On profitability, it posts an operating margin of -359.16%, a net margin of -353.00%, a Return on Equity (ROE) of -98.22%, a Return on Assets (ROA) of -82.29%, and a Return on Invested Capital (ROIC) of -146.10%. Per share, it reports EPS of $-1.58, diluted EPS of $-1.58, free cash flow per share of $-1.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -12.60% year-over-year, net income growth of 244.66% year-over-year, and EPS growth of 148.99% year-over-year. On the balance sheet, it maintains a current ratio of 0.82x, a quick ratio of 0.76x, working capital of $-329.00K, a debt-to-equity ratio of 0.36x, a debt ratio of 0.27, free cash flow of $-4.52M (TTM), and net debt of $-1.39M. Figures sourced from SEC EDGAR.
- Market Cap
- $100.88M
- P/E TTM
- -15.04x
- EPS TTM
- $-1.58
- P/B TTM
- 19.83x
- ROE TTM
- -98.22%
- ROA TTM
- -82.29%
- Debt To Equity
- 0.36x
- Free Cash Flow TTM
- $-4.52M
- Net Revenue TTM Growth 1Y
- -12.60%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cyclerion Therapeutics, Inc. in?
Cyclerion Therapeutics, Inc. (CYCN) operates in the Pharmaceutical Preparations industry.
What exchange does CYCN trade on?
Cyclerion Therapeutics, Inc. (CYCN) trades on the Nasdaq.
Where is Cyclerion Therapeutics, Inc. incorporated?
Cyclerion Therapeutics, Inc. is incorporated in MA.
When was Cyclerion Therapeutics, Inc. (CYCN)'s most recent SEC filing?
Cyclerion Therapeutics, Inc. (CYCN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is CYCN's market cap?
Cyclerion Therapeutics, Inc. (CYCN) has a market capitalization of $100.88M as of 2026-06-30.
What is CYCN's EPS (earnings per share)?
Cyclerion Therapeutics, Inc. (CYCN)'s trailing twelve month EPS is $-1.58 as of 2026-06-30.
What is CYCN's ROE (return on equity)?
Cyclerion Therapeutics, Inc. (CYCN)'s trailing twelve month Return on Equity (ROE) is -98.22% as of 2026-06-30.
What is CYCN's ROA (return on assets)?
Cyclerion Therapeutics, Inc. (CYCN)'s trailing twelve month Return on Assets (ROA) is -82.29% as of 2026-06-30.
What is CYCN's ROIC (return on invested capital)?
Cyclerion Therapeutics, Inc. (CYCN)'s trailing twelve month Return on Invested Capital (ROIC) is -146.10% as of 2026-06-30.
What is CYCN's EV/EBITDA?
Cyclerion Therapeutics, Inc. (CYCN)'s trailing twelve month EV/EBITDA is -14.58x as of 2026-06-30.